Litigation Details for Rochester Drug Co-Operative, Inc. v. Shire LLC (D. Mass. 2017)

Rochester Drug Co-Operative, Inc. v. Shire LLC (D. Mass. 2017)

Docket		Date Filed	2017-01-11
Court	District Court, D. Massachusetts	Date Terminated	2017-11-21
Cause	15:1 Antitrust Litigation	Assigned To	Allison Dale Burroughs
Jury Demand	Plaintiff	Referred To
Patents	6,287,599; 6,811,794
Link to Docket	External link to docket

Details for Rochester Drug Co-Operative, Inc. v. Shire LLC (D. Mass. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-01-11				External link to document
2017-01-10	1		5,854,290 (the ’290 patent), 6,287,599 (the ’599 patent), and 6,811,794 (the ’794 patent). 56. The…drug prior to the expiration of the listed patent(s). Patents issued after NDA approval may be listed in…verify the manufacturer’s patents for accuracy or trustworthiness. In listing patents in the Orange Book, the…listed several patents in the Orange Book as covering Intuniv, specifically, U.S. Patent Nos. 5,854,290…The ’290 patent is a method of use patent, entitled “Use of guanfacine in the treatment of behavioral disorders	External link to document

Rochester Drug Co-Operative v. Shire LLC, 1:17-cv-10050: Litigation Summary and Patent Analysis

Last updated: August 2, 2026

Rochester Drug Co-Operative, Inc. v. Shire LLC, No. 1:17-cv-10050, was a direct-purchaser antitrust action concerning Shire’s Lialda mesalamine product. The case alleged that Shire used its patent portfolio, regulatory filings, and infringement litigation to delay generic competition and maintain supracompetitive prices. The dispute was part of the broader Lialda antitrust litigation in the U.S. District Court for the Southern District of New York.

The case did not produce a trial judgment establishing that Shire violated the Sherman Act. The central litigation risk arose from allegations that Shire’s patent and regulatory conduct extended Lialda exclusivity beyond the protection available from a single valid patent.

What drug and market were at issue in Rochester Drug Co-Operative v. Shire?

The case involved Lialda, the brand name for mesalamine delayed-release tablets.

Item	Detail
Brand	Lialda
Active ingredient	Mesalamine, also called 5-aminosalicylic acid
Dosage form	Delayed-release oral tablet
Strength principally associated with Lialda	1.2 grams
Indication	Ulcerative colitis
Original developer	Shire and predecessor companies
Relevant market	Mesalamine delayed-release products used to treat ulcerative colitis
Plaintiff type	Direct pharmaceutical wholesaler
Court	U.S. District Court for the Southern District of New York
Case number	1:17-cv-10050
Filed	2017

Lialda competes with other mesalamine products, including Asacol HD, Delzicol, Pentasa and generic mesalamine formulations. The relevant competitive issue was whether Lialda’s formulation and delivery technology created a distinct market or whether it competed in a broader mesalamine market.

What conduct did Rochester Drug allege against Shire?

Rochester Drug alleged that Shire maintained Lialda’s monopoly through a coordinated exclusionary strategy. The allegations focused on:

1. Obtaining and enforcing patents covering Lialda’s formulation and delivery characteristics.
2. Filing patent infringement suits against generic applicants that submitted abbreviated new drug applications.
3. Using regulatory and patent procedures to delay FDA approval or commercial launch of generic mesalamine.
4. Maintaining multiple patent barriers around the product rather than relying only on the core composition or formulation patent.
5. Charging direct purchasers more than they would have paid in a competitive generic market.

The complaint framed the conduct under Section 2 of the Sherman Act. The theory was not that every patent assertion was unlawful. The theory was that Shire’s patent and litigation activity allegedly had no legitimate basis and was part of an exclusionary scheme designed to delay generic entry.

What were the main legal claims?

Walker Process fraud and sham litigation

The complaint pursued theories associated with Walker Process fraud and sham litigation. Under those theories, patent-related conduct can create antitrust exposure where:

• A patent was allegedly procured through intentional fraud on the U.S. Patent and Trademark Office; or
• Litigation was allegedly brought without a reasonable basis and for the purpose of interfering with competition.

These claims face a high pleading and evidentiary standard. A weak patent, a patent later invalidated, or an unsuccessful infringement case does not by itself establish antitrust liability.

Exclusionary conduct under Section 2

Rochester Drug also alleged that Shire unlawfully maintained monopoly power in the Lialda market. The required elements included:

• A relevant product market;
• Monopoly power or the dangerous probability of obtaining it;
• Exclusionary conduct rather than competition on the merits; and
• Antitrust injury caused by the conduct.

The alleged injury was delayed generic competition and the resulting overcharges paid by direct purchasers.

Patent misuse and regulatory manipulation theories

The case also implicated allegations that Shire improperly used patent listings, FDA procedures, or infringement litigation to impose barriers not justified by the scope of valid patent rights. Courts generally distinguish between lawful use of regulatory and patent systems and conduct that is objectively baseless, fraudulent, or designed principally to delay competition.

What patents protected Lialda?

Lialda was protected by a layered patent estate rather than one patent. The asserted and listed patents concerned the formulation, coating, release profile and delivery of mesalamine.

Publicly reported Lialda patent records include patents such as:

Patent	General subject matter	Relevance
U.S. Patent No. 6,773,720	Mesalamine formulation and delivery technology	Earlier Lialda protection
U.S. Patent No. 8,337,886	Formulation or delayed-release technology	Later patent barrier
U.S. Patent No. 8,865,688	Mesalamine delivery formulation	Product-specific protection
U.S. Patent No. 9,669,068	Additional formulation or release characteristics	Later Orange Book-listed protection

Patent scope and enforceability depended on the asserted claims, prosecution history, Orange Book listing status, and the defenses raised by each generic applicant. A patent’s inclusion in the Orange Book did not establish validity or infringement.

What was the generic-entry strategy?

A generic applicant seeking approval for Lialda could file an ANDA with a Paragraph IV certification asserting that listed patents were invalid, unenforceable or would not be infringed. The Paragraph IV notice would give Shire the opportunity to file an infringement action.

A timely infringement action could trigger a 30-month stay of FDA approval under the Hatch-Waxman Act, subject to statutory exceptions. The practical effect was to shift the dispute into federal patent litigation before a generic could launch.

The economic stakes were substantial because delayed-release mesalamine products required formulation work and could face multiple patent assertions. A generic applicant therefore had to evaluate:

• Formulation design-around options;
• The number of Orange Book-listed patents;
• Risk of a 30-month stay;
• Potential launch at risk;
• Patent-term adjustment and pediatric exclusivity;
• The likelihood of settlement; and
• State-law and federal antitrust exposure connected to the patent dispute.

Did the case involve a Paragraph IV challenge?

The antitrust complaint was based on the consequences of generic challenges to Lialda patents and Shire’s response to those challenges. The relevant generic-entry mechanism was the Paragraph IV process.

The docket and underlying patent disputes should be distinguished from the antitrust case itself. A Paragraph IV filing is a patent challenge, not an antitrust violation. Likewise, filing an infringement suit is generally protected petitioning activity unless the plaintiff can prove fraud or objectively baseless litigation under the applicable legal standard.

What was the Orange Book status of Lialda?

Lialda’s Orange Book position was important because listed patents could create a statutory approval stay after a Paragraph IV notice. The product’s exclusivity profile reflected several separate categories:

Protection	Function
New drug exclusivity	FDA regulatory protection following approval
Formulation patents	Protection for the delayed-release product
Method-of-use patents	Protection for treating specified conditions or patient groups
Patent-term adjustment	Potential extension of individual patent expiration
Pediatric exclusivity	Six-month extension where applicable
Litigation stay	Temporary FDA approval delay after qualifying patent litigation

Orange Book listing did not guarantee that every listed patent would survive litigation. Generic applicants commonly challenged the patents individually, designed around some claims, and accepted potential infringement risk for others.

When did Lialda lose exclusivity?

Lialda did not have one single exclusivity-loss date. The commercial loss of exclusivity depended on the interaction of:

• FDA regulatory exclusivity;
• Expiration of the principal formulation patents;
• Any patent-term adjustment;
• Pediatric exclusivity;
• Generic settlements;
• FDA approval timing; and
• The launch decisions of individual generic companies.

Generic mesalamine delayed-release products began entering the U.S. market after Lialda’s principal regulatory and patent barriers weakened. The first generic launch did not necessarily eliminate all Lialda patent protection because later patents could remain enforceable against specific formulations.

What was the procedural posture of the case?

Rochester Drug filed the action in the Southern District of New York in 2017. The case was litigated as a direct-purchaser antitrust action arising from the Lialda patent and generic-entry dispute.

The principal procedural issues included:

• Whether the complaint adequately pleaded a relevant antitrust market;
• Whether Shire possessed monopoly power;
• Whether the alleged patent conduct was exclusionary;
• Whether the complaint plausibly alleged fraud or objectively baseless litigation;
• Whether the plaintiffs adequately pleaded antitrust injury; and
• Whether the claims were barred by the Noerr-Pennington doctrine.

The case should not be characterized as a final finding that Shire’s Lialda patents were invalid or that Shire committed antitrust violations. The litigation involved pleading and procedural disputes, and the antitrust theories required proof beyond the existence of patents, regulatory filings or patent litigation.

What patent litigation affected Lialda generic entry?

The relevant litigation environment included Hatch-Waxman actions brought after ANDA applicants challenged Lialda patents. These cases determined whether generic products could launch before patent expiration and whether a particular generic formulation infringed Shire’s claims.

The commercial impact of those cases depended on the specific ANDA formulation. A generic could prevail against one patent while remaining exposed to another. Shire’s risk therefore depended on the cumulative strength of the estate rather than the survival of any single patent.

Did Shire settle with generic manufacturers?

The Lialda market involved the standard settlement-risk issues associated with Hatch-Waxman litigation. A settlement could establish an agreed generic-entry date, license generic entry before patent expiration, or resolve infringement claims without a final validity decision.

A settlement is not automatically unlawful. Under FTC v. Actavis, courts examine whether the settlement includes a large and unexplained reverse payment and whether that payment represents compensation for delayed entry rather than ordinary litigation or commercial considerations.[1]

The Rochester Drug claims sought to treat generic delay as anticompetitive harm to direct purchasers. The viability of that theory depended on proving that the alleged restrictions exceeded the legitimate exclusionary scope of valid patents.

How strong was Shire’s Lialda patent estate?

The estate was commercially meaningful but legally exposed.

Strengths

• Multiple patents created cumulative litigation barriers.
• Formulation patents can be difficult to design around where release timing and coating structure are central to product performance.
• ANDA litigation could delay approval even when a generic challenged the patents.
• The product’s clinical and commercial positioning supported a distinct formulation-based market argument.

Weaknesses

• Formulation patents often face written-description, enablement, obviousness and claim-construction challenges.
• Patent expiration dates limited the period during which Shire could exclude generics.
• A generic could challenge patents through Paragraph IV certifications.
• Orange Book listings did not establish validity or infringement.
• Antitrust plaintiffs could use the pattern of patent assertions and generic settlements to allege exclusionary intent, although intent alone was insufficient.

The estate was stronger as a portfolio than as an individual patent. Its value depended on whether generic applicants could invalidate the core claims, design around them, or obtain an agreed launch date.

What generic-entry risks existed for Lialda?

The principal generic-entry scenarios were:

Scenario	Commercial effect
Full patent victory for Shire	Generic approval or launch delayed until relevant patent expiration
Generic victory on core patents	Rapid erosion of Lialda pricing and volume
Design-around approval	Partial competition with possible formulation differences
Settlement with licensed entry	Predictable but potentially delayed generic launch
At-risk launch	Immediate price erosion with significant damages exposure if Shire later prevailed
Multiple generic approvals	Accelerated substitution and greater rebate pressure

For direct purchasers, the largest damages theory was the difference between actual Lialda prices and prices that would have prevailed after lawful generic entry.

What was the revenue exposure?

Lialda was one of Shire’s important gastrointestinal products before Shire was acquired by Takeda Pharmaceutical Company. The product generated substantial annual U.S. sales, making the timing of generic entry commercially significant.

Revenue exposure depended on:

• The number of approved generic competitors;
• Generic launch timing;
• Wholesale acquisition price reductions;
• Pharmacy substitution rates;
• Formulary decisions;
• The persistence of branded Lialda prescriptions; and
• Whether later patents covered commercially meaningful formulations.

The strongest antitrust damages period would have been the interval between the date generic competition allegedly should have begun and the date generic competition actually began. Damages would also require proof of causation, overcharge, pass-through treatment and the applicable statute of limitations.

How does Lialda compare with other mesalamine products?

Product	Formulation profile	Competitive issue
Lialda	Once-daily delayed-release mesalamine tablet	Formulation and release-control patents
Asacol HD	Delayed-release mesalamine tablet	Different delivery technology and patent estate
Delzicol	Encapsulated mesalamine formulation	Capsule-based delivery and product-specific patents
Pentasa	Extended-release mesalamine formulation	Distinct release profile and dosing
Generic mesalamine	Varies by manufacturer and formulation	Substitution depends on FDA product equivalence

The antitrust market definition was therefore contested. Rochester Drug had to show that Lialda competed in a market sufficiently narrow to support Shire’s alleged monopoly power. Shire could argue that physicians, payers and patients could substitute among mesalamine products and other ulcerative-colitis therapies.

What is the current litigation significance?

The case is significant as an example of direct-purchaser scrutiny of pharmaceutical patent strategies. It illustrates the difference between:

• Patent protection and antitrust exclusion;
• FDA listing and patent validity;
• Paragraph IV litigation and unlawful delay;
• Generic-entry timing and damages accrual; and
• A patent portfolio’s commercial strength and litigation defensibility.

The core business conclusion is that Lialda’s exclusivity depended on a portfolio of formulation and delivery patents, while the antitrust case challenged whether Shire used that portfolio lawfully. The existence of multiple patents increased generic-entry costs and delay risk but did not eliminate invalidity, design-around or antitrust exposure.

Key Takeaways

• Rochester Drug Co-Operative v. Shire concerned alleged anticompetitive protection of Lialda, not a conventional product-liability dispute.
• Lialda is mesalamine delayed-release tablets used for ulcerative colitis.
• The complaint challenged Shire’s use of formulation patents, Orange Book listings, Hatch-Waxman litigation and related regulatory conduct.
• Paragraph IV challenges were central to the generic-entry framework.
• A patent’s Orange Book listing did not establish validity or infringement.
• The antitrust theories required proof of fraud, objectively baseless litigation or other exclusionary conduct beyond ordinary patent enforcement.
• Lialda’s patent estate was layered and commercially significant, but its strength depended on the specific claims and generic formulation at issue.
• Generic-entry timing was the primary driver of potential direct-purchaser damages.
• The case did not establish a final merits finding that Shire violated antitrust law.
• The litigation is best analyzed together with Lialda’s Orange Book history, ANDA challenges, patent settlements and generic launch chronology.

FAQs

Was Rochester Drug Co-Operative a class action?

The case was brought by a direct pharmaceutical purchaser and was part of broader direct-purchaser antitrust litigation. Class certification and consolidation issues depended on the operative pleadings and docket orders.

Did the case invalidate Shire’s Lialda patents?

No. An antitrust complaint does not invalidate patents. Patent validity and infringement are determined in patent proceedings or through settlement and judgment.

Did Lialda have method-of-use patents?

The principal commercial dispute centered on formulation and delivery protection. Any method-of-use patents had to be evaluated separately by claim scope, Orange Book listing and the FDA-approved labeling covered by the patent.

Could a generic launch before every Lialda patent expired?

Yes. A generic could launch after prevailing on key patents, designing around asserted claims, obtaining a license, or accepting at-risk launch exposure. Expiration of one patent did not necessarily remove all barriers.

What company acquired Shire and assumed Lialda exposure?

Takeda Pharmaceutical Company completed its acquisition of Shire in 2019. Takeda therefore became the principal corporate successor for Shire’s pharmaceutical assets, subject to the structure of the transaction and any retained rights or liabilities.

References

1. Federal Trade Commission v. Actavis, Inc., 570 U.S. 136 (2013).

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. District Court for the Southern District of New York. (2017). Rochester Drug Co-Operative, Inc. v. Shire LLC, No. 1:17-cv-10050.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center. USPTO.

5. Takeda Pharmaceutical Company Limited. (2019). Takeda completes acquisition of Shire. Takeda.